source
- US biotech faces regulatory push as China licensing deals spark security concernsA surge in licensing agreements between Chinese pharmaceutical firms and U.S. biotech companies has been noted, with nearly 100 deals announced since early 2025, prompting worry among investors and…
- Alkermes CEO targets orexin market after strong narcolepsy pill dataAlkermes' incoming chief executive outlined a strategy to compete with larger rivals in the emerging orexin drug class. Recent mid-June trial results showed the experimental oral compound alixorex…